|Day Low/High||2.95 / 3.12|
|52 Wk Low/High||2.14 / 4.71|
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Here's a list of October's potentially stock-moving biotech events.
Vertex moves ahead with late but competitive pill for rheumatoid arthritis, a $12 billion treatment market.
Rigel Pharmaceuticals (Nasdaq:RIGL) is trading at unusually high volume Thursday with 1.3 million shares changing hands. It is currently at 4.6 times its average daily volume and trading down 24 cents (-2.8%).
Rigel Pharmaceuticals (Nasdaq:RIGL) has been downgraded by TheStreet Ratings from from a hold to sell.
Several stocks trading under $10 were poised to move on above-average volume during Tuesday's session.
Rigel could receive $1.245 billion in a license agreement for its rheumatoid arthritis drug with AstraZeneca.
Sell-side firms release optimistic outlooks for the biotech sector.
Rigel Pharmaceuticals shares rise on RBC Capital Markets analyst upgrade
Worldwide deal involves privately held Alder BioTherapeutics
Rigel Pharmaceuticals' 3rd-quarter loss narrows on lower stock, development costs
If the troubled hedge fund liquidates, it will sell biotech stocks.
Big Pharma is seeking deals with biotech, specialty pharma, analyst says
Rigel's oral medicine, R788, significantly improved the symptoms of rheumatoid arthritis patients in a study compared with a placebo, but as in previous studies high blood pressure emerged as a leading side effect.
New data for Rigel's rheumatoid arthritis pill could ease safety fears and open doors for a lucrative deal.
A quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.
Movers roundup: Rigel Pharma gains on arthritis drug potential, Mueller Water Products rises
Rodman & Renshaw analyst expects Rigel Pharmaceuticals arthritis drug to perform well
Rigel shares were falling after the small drug maker announced plans to cut its workforce and delay partnership plans for a key rheumatoid arthritis drug.
Scores of smaller biotech firms have unpartnered drugs in the pipeline, making them ripe for alliances or takeovers.
Shares of Rigel tanked late Monday, as the company presented data for experimental arthritis treatment R788.
An experimental pill from Incyte reduced symptoms in rheumatoid arthritis patients, according to results from a small phase II study presented Sunday.
The stock takes a beating after company ends late-stage trial of GVAX.
If Roche is serious about buying the company, it will need to do much better than $89 a share.
The January numbers will likely trigger a buying spike that will lift the major indices to new recovery highs.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.